Are elevated plasma asymmetric dimethylarginine (ADMA) levels an early marker for endothelial dysfunction in children with beta-thalassemia major?
Elevated plasma ADMA levels may serve as an early biomarker for endothelial dysfunction and premature atherosclerosis risk in children with beta-thalassemia major.
The findings of the current study show us that increased plasma ADMA levels in children with beta-thalassemia major may be an early marker for endothelial dysfunction and may play a role in the development of premature atherosclerosis in beta-thalassemia major patients.
Gürsel et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: